In the wake of new programs that produce artwork derived from existing media, ChatGPT, and even algorithms that can predict protein folding, it is evident that the age of artificial intelligence (AI) is upon us. In many cases, the AI programs and tools are far more advanced than we have previously seen, to the point where humanity can derive great benefit from AI while fearing how it may affect our society and livelihoods. While it is unlikely that we will be subjugated by our new robot overlords, it is still important to explore what has been done and remains possible through AI, and our considerations for its ethical usage.

It is always a thrill and a privilege to share our customers' success stories with you, particularly when they feature ABclonal's products in their research publications. Over the past year, we have seen many citations of our reagents in multiple journals, showcasing the partnership ABclonal maintains as a trusted lab partner across a wide range of disciplines. In this entry, we will highlight some of the catalog and custom antibody products our valued customers used to generate recent publication-quality research that adds to our collective understanding of biology!

The dream of biomedical researchers is to fine-tune their therapeutics to precisely target the specific illness or pathogen affecting their patient. Ever since Nobel laureate and oft-quoted father of immunology, Paul Ehrlich, coined the term “magic bullet,” medical science has marched towards more personalized drugs that target key molecules that cause diseases including cancer. ¹ We find ourselves now, over a century later, in an exciting era of discovery that has produced many antibody drug conjugates (ADC) designed to precisely target the diseased cells and not healthy cells. ADC uses this strategy to take advantage of the specificity of antibodies while delivering a covalently linked cytotoxic payload directly to diseased tissues to reduce the multitudes of side effects and toxicity. ^{2, 3} As basic research identifies more targets and antibody engineering procedures improve, the range of antitumor and anti-disease weapons may seem limitless. 

I recall having to make hundreds of custom peptides, and even though we used an automated peptide synthesizer rather than doing it by hand like another lab in the building, making a dozen peptides at a time still took hours on the machine and then another couple days for the purification and lyophilization processes. My mentor and I briefly joked about using bacteria and a polycistronic construct to just have the little guys use their ribosomes to do it for us, but the purification process probably would have been impractical. This does make me appreciate the wonders of natural biosynthetic machinery, and I promise there is a point here because we still use animal hosts to initially produce antibodies. Today, let's explore the process by which most commercial and custom antibodies are still produced, including here at ABclonal!

When you consider which of the dozens of biological reagents companies to work with, how can you determine which one is the right fit? There is, of course, a business aspect to making and distributing quality antibody reagents. The source of the antibodies that you rely on for your research will matter in terms of supply consistency, lead time, cost, and the associated services to support your product. 

The 2021 Nobel Prize in Physiology of Medicine was awarded jointly to David Julius, of the University of California at San Francisco, and Ardem Patapoutian, a neuroscience researcher at the Scripps Research Institute in La Jolla, California. Working independently, Julius and Patapoutian discovered the key receptors (TRPV1, TRPM8, Piezo1, and Piezo2) in our bodies that sense heat, cold, and touch. Their work not only helps us to understand how we perceive and adapt to the surrounding world, but also paves the way for drug discoveries that target a wide range of diseases, including chronic pain, respiratory disease, and cancer.